1. bookVolume 21 (2013): Issue 3 (September 2013)
Journal Details
License
Format
Journal
eISSN
2284-5623
ISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Eosinophil activation markers in clonal and non-clonal eosinophilia

Journal Details
License
Format
Journal
eISSN
2284-5623
ISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Eosinophils are leukocytes with multiple functions in physiologic and pathologic circumstances. Eosinophilia is typically associated with reactive conditions (helmintic infections, allergic or drug reactions and atopic disorders) and sometimes with hematologic and non- hematologic malignancies. Evaluation of a patient with eosinophilia requires numerous imaging investigations and laboratory tests for establishing the right treatment. We measured the degree of eosinophilic activation using serologic biomarkers such as serum eosinophil cationic protein (ECP) , interleukin-5 (IL-5) and eosinophilic cationic protein/eosinophil count (ECP/Eo) ratio in order to differentiate earlier among distinct eosinophilic conditions: clonal, non-clonal with malignancy and reactive eosinophilia with inflammation. The median ECP value in eosinophilic patients was significantly higher when compared to that of the control group (19.55 vs. 4.93 ng/mL, p<0.05). Within patients with eosinophilia, the clonal eosinophilia group showed a significantly higher median ECP value compared to the median ECP values of the non-clonal eosinophilia groups - (30.15 vs. 19.5 ng/mL, p<0.05 and respectively 30.15 vs. 13.3 ng/mL, p<0.05). Also patients having non-clonal eosinophilia with malignancy had a significantly higher median ECP value compared to those of reactive eosinophilia and inflammation (19.5 vs. 13.3 ng/mL, p<0.05). While ECP serum levels seemed to be a discriminatory tool for different groups of eosinophilic patients IL-5 and ECP/Eo were less useful for this purpose. However our results must be confirmed in larger studies

Keywords

Cuvinte cheie

1. Rosenberg H.F.,Dyer K.D.,Foster P.S. Eosinophils: changing perspectives in health and Disease. Nat Rev Immunol. 2013 Jan;13(1):9-22.10.1038/nri3341Search in Google Scholar

2. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008 May;38(5):709-50.10.1111/j.1365-2222.2008.02958.xSearch in Google Scholar

3. Jacobsen EA,Richard A. Helmers2, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012 Nov 8;120(19):3882-90.10.1182/blood-2012-06-330845Search in Google Scholar

4. Horny HP, Sotlar K, Valent P. Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. Journal of Hematopathology. 2011;4(2):101-111.10.1007/s12308-011-0094-8Search in Google Scholar

5. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun;133(5):468-92.10.1111/j.1365-2141.2006.06038.xSearch in Google Scholar

6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.10.1182/blood-2009-03-209262Search in Google Scholar

7. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophilic disorders. Blood Rev. 2009 Jul;23(4):157-65.10.1016/j.blre.2009.01.001Search in Google Scholar

8. Chusid MJ, Dale CD, West BC, Wolff SM .The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975 Jan;54(1):1-27.10.1097/00005792-197501000-00001Search in Google Scholar

9. Park YJ, Oh EJ, Park JW, Kim M, Han K. Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. Ann Clin Lab Sci. 2006;36(3):262-6.Search in Google Scholar

10. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999 Sep;29(9):1172-86.10.1046/j.1365-2222.1999.00542.xSearch in Google Scholar

11. Davies L, Gather U. The Identification of Multiple Outliers. Journal of the American Statistical Association. 1993 Sep;88(423):782-92.10.1080/01621459.1993.10476339Search in Google Scholar

12. Rousseeuw PJ, Croux C. Alternatives to the Median Absolute Deviation. Journal of the American Statistical Association. 1993 Sep;88(424):173-83.10.1080/01621459.1993.10476408Search in Google Scholar

13. Mizera I, Muller CH. Location-Scale Depth. Journal of the American Statistical Association. 2004 Dec;99(468):949-89.10.1198/016214504000001312Search in Google Scholar

14. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol. 2010 Mar;17(2):117-24.10.1097/MOH.0b013e3283366c70Search in Google Scholar

15. Liso V., Troccoli G., Specchia G. and Magno M. Cytochemical “normal” and “abnormal” eosinophils in acute leukemias. Am J Hematol. 1977;2(2): 123-31.10.1002/ajh.2830020204Search in Google Scholar

16. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol. 2009 Jan;9(1): 9-13.10.1038/nri2458Search in Google Scholar

17. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999 Mar 1;93(5):1651-7.10.1182/blood.V93.5.1651.405k20_1651_1657Search in Google Scholar

18. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14.10.1056/NEJMoa025217Search in Google Scholar

19. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007 Aug 10;25(23): 3503-10.10.1200/JCO.2006.08.5696Search in Google Scholar

20. Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin K, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003 May 1;101(9):3386-90.10.1182/blood-2002-03-0947Search in Google Scholar

21. Roufosse F, Garaud S, de Leval L. Lymphoproliferative Disorders Associated With Hypereosinophilia. Semin Hematol. 2012 Apr;49(2):138-48.10.1053/j.seminhematol.2012.01.003Search in Google Scholar

22. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000 Feb 15;95(4):1207-13.10.1182/blood.V95.4.1207.004k34_1207_1213Search in Google Scholar

23. Stanelle J, Doring C, Hansmann ML, Kuppers R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells. Blood. 2010 Nov 18;116(20):4202-11.10.1182/blood-2010-01-265827Search in Google Scholar

24. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011 Feb; 12(2):151-9.10.1038/ni.1981Search in Google Scholar

25. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007 Apr 1;178(7):4222-9.10.4049/jimmunol.178.7.4222Search in Google Scholar

26. Cormier S, Taranova A, Bedient C, Nguyen T, Protheroe C, Pero R et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006 Jun; 79(6):1131-9. 10.1189/jlb.0106027Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo